|By PR Newswire||
|August 21, 2013 08:01 AM EDT||
NEW YORK, August 21, 2013 /PRNewswire/ --
Today, Investors' Reports announced new research reports highlighting Opko Health, Inc. (NYSE: OPK), Sirona Dental Systems Inc. (NASDAQ: SIRO), Accuray Incorporated (NASDAQ: ARAY), Techne Corp. (NASDAQ: TECH), and Steris Corp. (NYSE: STE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Opko Health, Inc. Research Report
On August 9, 2013, Opko Health, Inc. (Opko) reported its Q2 2013 financial results with consolidated revenues of $23.8 million, compared to $10.2 million in Q2 2012. Net loss for the quarter totaled $3.4 million, compared to net loss of $10.8 million in Q2 2012. "We continue to build and strengthen the foundation for a sound profitable business," said Phillip Frost, M.D., OPKO's Chairman and CEO. "We are also very proud of the pipeline of new products in various stages of development in OPKO and soon to be acquired PROLOR. They can provide the basis for an important health care company." The Full Research Report on Opko Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/OPK]
Sirona Dental Systems Inc. Research Report
On August 2, 2013, Sirona Dental Systems Inc. (Sirona) reported its Q3 FY 2013 financial results (period ended June 30, 2013) with revenue growth of 17.0% YoY to $283.2 million. Gross profit margin was 53.5% compared to 53.1% in Q3 FY 2012. Net income came in at $40.6 million or $0.72 per diluted share, higher compared to $30.3 million or $0.53 per diluted share in Q3 FY 2012. Commenting on the Company's future outlook, Jeffrey Slovin, President and CEO of Sirona said, "We are on track for a third consecutive year of double digit revenue growth clearly demonstrating the strength of our organization. We continue to take market share and are well positioned for future growth." The Full Research Report on Sirona Dental Systems Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/SIRO]
Accuray Incorporated Research Report
On August 7, 2013, Accuray Inc. (Accuray) announced that it has scheduled to release its Q4 FY 2013 and full-year FY 2013 (period ended June 30, 2013) financial results on August 27, 2013, after the market closes. On the same day, the Company will hold a conference call at 2:00 p.m. PDT to discuss the results, which will be hosted by Joshua H. Levine, President and CEO and Derek Bertocci, Senior Vice President and CFO. The Full Research Report on Accuray Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/ARAY]
Techne Corp. Research Report
On August 6, 2013, Techne Corp. (Techne) reported its Q4 FY 2013 and full-year FY 2013 financial results (period ended June 30, 2013). Net sales for the quarter totaled $79.5 million, up 1.0% YoY. Q4 FY 2013 earnings totaled $28.4 million or $0.77 per diluted share, as compared with $27.2 million or $0.74 per diluted share in Q4 FY 2012. For full-year FY 2013, net sales declined 1.3% YoY to $310.6 million. The Company reported that a stronger U.S. dollar as compared to foreign currencies reduced year-on-year sales by $2.6 million in full-year FY 2013. Earnings for the full-year FY 2013 came in at $112.6 million or $3.05 per diluted share, as compared with $112.3 million or $3.04 per diluted share in FY 2012. The Full Research Report on Techne Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/TECH]
Steris Corp. Research Report
On August 7, 2013, Steris Corp. (Steris) reported its Q1 FY 2014 financial results (period ended June 30, 2013). Revenues for the quarter increased to $367.7 million, compared with $337.0 million in Q1 FY 2013. Net income came in at $32.3 million or $0.54 per diluted share, slightly higher compared with net income of $30.4 million or $0.52 per diluted share in Q1 FY 2013. Commenting on the future outlook of the Company, Walt Rosebrough, President and CEO of STERIS said, "We continue to see stable market trends, good performance from the businesses we recently acquired, and strong Healthcare orders and backlog, which gives us confidence in our ability to deliver revenue and earnings in-line with our guidance for the year." The Company re-affirmed its outlook for full-year FY 2014 with revenue growth in the range of 8% to 10% YoY and adjusted EPS in the range of $2.47 to $2.60. The Full Research Report on Steris Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-14/STE]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Investors' Reports